The 8 Largest US Funding Rounds of November 2023 – AlleyWatch alleywatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alleywatch.com Daily Mail and Mail on Sunday newspapers.
Global insurer Zurich has appointed Drazen Jaksic to the role of Chief Executive Officer (CEO) Benelux. Based in Brussels, Jaksic will report to Sierra
Forty percent of patients who filled a prescription for Novo Nordisk's Wegovy to treat obesity in 2021 or 2022 were still taking it a year later, more than three times the rate of adherence with older medicines, according to an analysis of medical records and insurance claims data. Only 13% of patients who started taking Contrave from Orexigen Therapeutics and 10% of those who started on Qsymia from Vivus between 2015 and 2022 were still filling their prescriptions a year later, researchers reported on Wednesday in the journal Obesity. The findings involved 1,911 adults, 25% of whom received Wegovy, which belongs to a new class of anti-obesity medications known as GLP-1 agonists originally developed to treat type 2 diabetes.